About
Technology
Issues
FAQ
Search
Scientometrics
Impact Factor
Discipline Ranks
h
-index
g
-index
Articles
Citations
Article Citations
Citation Distribution
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Journals
›
Chinese Clinical Oncology
›
top-articles
Chinese Clinical Oncology
1.6
(top 50%)
impact factor
647
(top 20%)
papers
6.6K
(top 20%)
citations
35
(top 20%)
h
-index
1.8
(top 50%)
impact factor
801
all documents
7.3K
doc citations
52
(top 20%)
g
-index
Top Articles
#
Title
Journal
Year
Citations
1
Intrahepatic cholangiocarcinoma: the AJCC/UICC 8th edition updates
Chinese Clinical Oncology
2018
142
2
Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency
Chinese Clinical Oncology
2016
131
3
Advanced magnetic resonance imaging in glioblastoma: a review
Chinese Clinical Oncology
2017
119
4
The emerging role of oncolytic virus therapy against cancer
Chinese Clinical Oncology
2018
105
5
Epidemiology of ovarian cancer
Chinese Clinical Oncology
2020
101
6
Staging and response assessment in lymphomas: the new Lugano classification
Chinese Clinical Oncology
2015
99
7
Genetic and epigenetic landscape of nasopharyngeal carcinoma
Chinese Clinical Oncology
2016
94
8
Biliary tract cancers: epidemiology, molecular pathogenesis and genetic risk associations
Chinese Clinical Oncology
2016
94
9
Epidemiology of gallbladder cancer in India
Chinese Clinical Oncology
2019
90
10
Gallbladder cancer: epidemiology and genetic risk associations
Chinese Clinical Oncology
2019
89
11
A review of hepatocellular carcinoma (HCC) staging systems
Chinese Clinical Oncology
2013
70
12
Advances in systemic treatment for nasopharyngeal carcinoma
Chinese Clinical Oncology
2016
69
13
Classification of meningiomas—advances and controversies
Chinese Clinical Oncology
2017
66
14
Immunotherapy for metastatic breast cancer
Chinese Clinical Oncology
2018
66
15
Immunotherapy for nasopharyngeal cancer—a review
Chinese Clinical Oncology
2016
60
16
Systemic therapy for esophageal cancer: chemotherapy
Chinese Clinical Oncology
2017
55
17
An overview of the NCI precision medicine trials-NCI MATCH and MPACT
Chinese Clinical Oncology
2015
53
18
Thermal ablation for hepatocellular carcinoma: what’s new in 2019
Chinese Clinical Oncology
2019
51
19
Cost-comparativeness of proton versus photon therapy
Chinese Clinical Oncology
2016
51
20
The inflammatory microenvironment in brain metastases: potential treatment target?
Chinese Clinical Oncology
2015
51
21
Clinical utility of circulating Epstein-Barr virus DNA analysis for the management of nasopharyngeal carcinoma
Chinese Clinical Oncology
2016
47
22
MicroRNAs in nasopharyngeal carcinoma
Chinese Clinical Oncology
2016
47
23
Systemic therapy for hepatocellular carcinoma: beyond sorafenib
Chinese Clinical Oncology
2018
47
24
Prognostic scores for brain metastasis patients: use in clinical practice and trial design
Chinese Clinical Oncology
2015
47
25
Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)
Chinese Clinical Oncology
2016
46
26
The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2- invasive breast cancer
Chinese Clinical Oncology
2015
45
27
Neoadjuvant treatment for HER2-positive breast cancer
Chinese Clinical Oncology
2020
44
28
Preclinical models of pancreatic ductal adenocarcinoma
Chinese Clinical Oncology
2017
44
29
Precision medicine in breast cancer
Chinese Clinical Oncology
2018
44
30
BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management
Chinese Clinical Oncology
2014
44
31
Proton therapy for the management of uveal melanoma and other ocular tumors
Chinese Clinical Oncology
2016
42
32
Pathologic classification of “pancreatic cancers”: current concepts and challenges
Chinese Clinical Oncology
2017
42
33
Reirradiation of locally recurrent nasopharyngeal cancer: history, advances, and promises for the future
Chinese Clinical Oncology
2016
41
34
Management of fibrolamellar hepatocellular carcinoma
Chinese Clinical Oncology
2018
40
35
Gallbladder cancer: surgical management
Chinese Clinical Oncology
2019
39
36
New approaches in primary central nervous system lymphoma
Chinese Clinical Oncology
2015
39
37
An overview of the design and conduct of the BATTLE trials
Chinese Clinical Oncology
2015
39
38
Immune checkpoint inhibitor therapy in biliary tract cancer (cholangiocarcinoma)
Chinese Clinical Oncology
2020
38
39
Update on skin directed therapies in mycosis fungoides
Chinese Clinical Oncology
2019
38
40
Biomarkers of neoadjuvant/adjuvant chemotherapy for breast cancer
Chinese Clinical Oncology
2020
37
41
Surgical margins in the management of extremity soft tissue sarcoma
Chinese Clinical Oncology
2018
36
42
Guidelines on the diagnosis and treatment of primary liver cancer (2011 edition)
Chinese Clinical Oncology
2012
36
43
Genetic susceptibility to the endemic form of NPC
Chinese Clinical Oncology
2016
35
44
Risk factors for developing hepatocellular carcinoma in Egypt
Chinese Clinical Oncology
2013
35
45
Primary extranodal B-cell lymphoma: current concepts and treatment strategies
Chinese Clinical Oncology
2015
35
46
Epidemiology of pancreatic adenocarcinoma
Chinese Clinical Oncology
2017
34
47
Proton therapy for nasopharyngeal carcinoma
Chinese Clinical Oncology
2016
33
48
Combined intrahepatic cholangiocarcinoma and hepatocellular carcinoma
Chinese Clinical Oncology
2016
33
49
Systemic therapy of cutaneous T-cell lymphoma (CTCL)
Chinese Clinical Oncology
2019
33
50
Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling
Chinese Clinical Oncology
2019
33
site/software ©
exaly
; All materials licenced under
CC by-SA
.